

# Personalised control and prevention of progression of COPD by a software based scientific expert system

**WISE-Breath technology** 

## **Clinical Value Proposition**

New tool for Medical doctors and Health providers to reduce COPD progression in their patients/clients through the continuous and daily support of these patients by recommendations related to their particular COPD disease situation.

Reduction in mortality, exacerbations, Health associated costs

## **Patients Value Proposition**

Involvement of self-control of its own disease preventing its progression and achieving better life quality and longer life expectancy.

Recommendations and personalized alarms adapted for each patient disease and environment.

### **Product**

Wise Breath Implemented technology for use in personal mobile phones by COPD patients through private permission access by payment by Health providers.

#### Market introduction

Estimated time to market 1-2 years.

#### Scientific and Clinician Team

- Clinicians & researchers multidisciplinary team of several disciplines. Technology based on integration analysis from robust patients cohort's publication analysis, enriched from diverse data sources at different levels and done by a clinical expert group From CIBERES and Hospital 12 de Octubre..
- The IP is a MsD Doctor in Epidemiology and Public Health and specialist in data analysis.
- 100% owners of technology.
- Under registry and secret protection
- Currently under software development and technical validation in patients.


COPD is a complex chronic respiratory disease with a serious impact on the quality of patients' life, is fourth leading cause of death and has a high cost to health systems.

Scientific and clinical data show that patients with chronic diseases (such as COPD) actively involved in their self-care maintain their functionality and quality of life for longer.

Prevention and maintenance of the progression of COPD depends of: the disease control, the exacerbations control, the adherence to treatment, the correct use of medical devices, the respiratory training, the exposure to environmental risk factors, etc. COPD associated costs are mainly due to: 40-45% Hospitalisation Expenditure; 30-45% Drugs; 15-25% Visits and diagnostic tests.

Reducing uncontrolled risk factors is expected to accumulate a calculated reduction of about 50% of associated Health costs.

Improving the prevention and progression of COPD by an active involvement of the patient in control of his COPD situation with a personalised support expert system.



Our expert system is an algorithm generated from the integration analysis of several robust publications of scientific and clinical analysis from more than 200 variables in a big and robust cohort patients plus enriched with diverse health conditions of the patient and environment.

The product is presented as a software to use by COPD patients that, after an easy inclusion of their personal and health data, them will provide permanent access to personalized recommendations and alerts to contribute to the progression disease control. It will anticipate and reduce exposure to risk factors, enhance adherence to treatments and support them with information and recommendations for decision-making s.

Physicians will also improve treatment efficacy control and healthcare providers will achieve a reduction in healthcare costs.

Disclaimer

This document has been prepared by the owners of the IP to a limited number of parties who may be interested in entering into a partnership with them or in licensing. The sole purpose of this document is to assist the recipient in deciding whether to proceed with a further investigation of the asset and owners and its offerings.

with a further investigation of the asset and owners and its offerings.

This document has been prepared on the basis of several sources of information, including public information. Owners shall make any representation or warranty, expressed or implied, as to the accuracy or completeness of the document or the information contained herein. The owners shall have any responsibility for the use of this document and the information contained herein.



# **Investment and Partnering opportunity**

# **WISE- Breath Expert System for COPD self-management**

# **Opportunity**

CIBER offers collaboration for the development of the product and its validation as well as seeks investment to take the product to the market.

The first target market is **Health assurance companies** to offer better COPD control to their customers, better medical outcome to their physicians and reduce health costs for the company. The use of the technology can be provided also from Public Health System.

The same methodology can be developed by the team for other related pathologies, such as for Asthma and in the current pandemic context for better individual disease control: Patients with previous chronic diseases, as COPD, have a greater risk for COVID-19 infection.

#### **Target Product Profile**

Label A software to p

A software to provide COPD patients with all the tools to self-control their disease progression.

Pricing:

Similar to those in the market for health-care software for use in mobile phone by private access under a license.

# **Key Economical Considerations**

- Market 12% of adult population beyond 40 only in Spain 2.2 M.
- Reduction of hospitalization costs estimated in 50%. About 1200€/patient/year.
- Reduction of exacerbations and mortality by better disease control.

# Contact

Cristina Broceño Corrales, PhD. CIBERES' Technology Transfer Manager

Mobile: +34 674 097 109 E-mail: cbroceno@ciberes.org

### The tool for

The product is a software to be used from COPD patient's personal mobile phones.

The use will be through the payment of a personal licence access.

It is expected that payers will be health providers.

The first market could be main health insurance companies, that will provide them with a competitive value as well as will reduce their health associated cost/ patient.

#### **IP and Know How**

Knowledge data base registered and algorithm and software under secret protection.

# **Easy adoption**

The tool is

|                                   | Clinical Value                                                                                  | Economic Value                                               |
|-----------------------------------|-------------------------------------------------------------------------------------------------|--------------------------------------------------------------|
|                                   | Daily self-control of his current health situation.                                             | Treatment family costs reduction.                            |
| Patient                           | Disease progression reduction, complications reduction, better life quality, survival increase. |                                                              |
|                                   | Complications and deaths reduction.                                                             | Reduced risk of                                              |
| Physicians                        | Higher accuracy treatments.                                                                     | complications and deaths' associated costs.                  |
|                                   | Better adherence.                                                                               | Reduction of the specialized assistance need frequency       |
|                                   | Health interventions evaluation and follow up                                                   | accidance need needs.                                        |
| Software/<br>eHealth<br>companies | Competitive value for companies offering new clinical information to final costumers.           | High market volume for a chronic and very prevalent disease. |
| HealthCare                        | Reductions of % mortality.                                                                      | Hospitalization, diagnostic and treatments costs             |
| Providers                         | Reduction of long hospitalizations.  Better disease's control.                                  | reduction.                                                   |
|                                   | Detter disease's control.                                                                       |                                                              |

# **Current Situation of the Technology.**

Software is under development.

Clinical market validation studies are in progress.

Currently the team studies other scientific results to achieve new algorithms for use in related pathologies.